Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596882 · ClinicalTrials.gov registry record · Phase 4
Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00596882: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT00596882 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00596882, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The proposed study has been designed to examine the effect of a message that primes genetic susceptibility on actual enrollment in a smoking cessation program, actual response to smoking cessation treatment, and potential moderators and mediators of this effect.
Interventions
- OTHER Message Prime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00596882
The ClinicalTrials.gov registry entry for NCT00596882 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Message Prime is the first listed.
NCT00596882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00596882 about?
NCT00596882 is a clinical study titled "Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study". The proposed study has been designed to examine the effect of a message that primes genetic susceptibility on actual enrollment in a smoking cessation program, actual response to smoking cessation treatment, and potential moderators and mediators of this effect.
What is the current status of trial NCT00596882?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2008-02. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00596882?
The interventions under investigation include: Message Prime (OTHER).
Who is sponsoring clinical trial NCT00596882?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.